SCHEMBL23355337

SCHEMBL23355337

COC(=O)c1cccc(Oc2ccc(NC(=O)OC(C)(C)C)c(F)c2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.47
RAB9A P51151 4/20 0.47
NPC1 O15118 3/20 0.47
KDR P35968 2/20 0.46
FLT1 P17948 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CYP17A1 P05093 1/20 0.45
POLB P06746 1/20 0.45
HTT P42858 1/20 0.45
TP53 P04637 1/20 0.42
LMNA P02545 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23355361 0.90 NPC1 (0.49) SMN1; SMN2RAB9ANPC1KDRFLT1
SCHEMBL23355328 0.89 MAPT (0.48) SMN1; SMN2RAB9ANPC1CYP17A1POLB
SCHEMBL30203162 0.89 MAPT (0.48) SMN1; SMN2RAB9ANPC1CYP17A1POLB
SCHEMBL23355461 0.87 RAB9A (0.48) SMN1; SMN2RAB9ANPC1KDRFLT1
SCHEMBL30203156 0.87 RAB9A (0.48) SMN1; SMN2RAB9ANPC1CYP17A1POLB
SCHEMBL23368134 0.87 RAB9A (0.48) SMN1; SMN2RAB9ANPC1CYP17A1POLB
SCHEMBL23355365 0.86 L3MBTL1 (0.51) SMN1; SMN2RAB9ANPC1L3MBTL1TP53
SCHEMBL23368165 0.86 RAB9A (0.47) SMN1; SMN2RAB9ANPC1KDRFLT1
SCHEMBL23368105 0.85 RAB9A (0.47) SMN1; SMN2RAB9ANPC1CYP17A1POLB
SCHEMBL30203071 0.85 RAB9A (0.47) SMN1; SMN2RAB9ANPC1CYP17A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230025510-A1 BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-01-26 US disclosed
US-20230025510-A1 BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-01-26 US disclosed
EP-3822263-A1 BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2021-05-19 EP disclosed
CN-112334460-A Biaryl ether type quinazoline derivative 第一三共株式会社 2021-02-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230025510-A1 BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES ERBB2, EGFR, ERBB3 SMN1; SMN2 4676/4885RAB9A 667/4885NPC1 2118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.